GeoVax to Showcase Vaccine and Immunotherapy Progress at Emerging Growth Conference
TL;DR
GeoVax Labs' upcoming presentation at the Emerging Growth Conference offers investors a strategic advantage by detailing progress on vaccines and therapies with significant market potential.
GeoVax Labs will discuss the development stages of GEO-MVA, GEO-CM04S1, and Gedeptin®, including Phase 2 trials and regulatory advancements, during their July 16 presentation.
GeoVax Labs' innovations in vaccines and cancer therapies aim to improve global health by addressing critical gaps in pandemic readiness and treatment options.
Discover how GeoVax Labs is revolutionizing vaccine and cancer therapy development with their MVA platform and gene-directed enzyme prodrug therapy at the Emerging Growth Conference.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025. The presentation will feature Chairman and CEO David Dodd discussing the company's pipeline, including the GEO-MVA vaccine for Mpox/smallpox, the GEO-CM04S1 COVID-19 vaccine, and Gedeptin®, a therapy for solid tumors. The event offers a platform for shareholders and the investment community to engage directly with the company's leadership.
The GEO-MVA vaccine, designed for global preparedness against Mpox and smallpox, has recently received favorable feedback from the European Medicines Agency. Meanwhile, the GEO-CM04S1 vaccine is undergoing Phase 2 trials to assess its efficacy in immunocompromised individuals and as a booster for healthy adults. Gedeptin® is advancing towards a Phase 2 trial for head and neck cancer, showcasing GeoVax's commitment to addressing unmet medical needs.
GeoVax's presentation will also emphasize the role of its MVA platform and U.S.-based manufacturing in enhancing vaccine supply diversification and pandemic readiness. The conference represents a significant opportunity for stakeholders to gain insights into GeoVax's strategic direction and the potential impact of its programs on public health and biosecurity.
Interested parties can register for the conference here, with a replay available post-event on the Emerging Growth website and YouTube channel. This engagement underscores GeoVax's dedication to transparency and innovation in the biotechnology sector.
Curated from NewMediaWire
